Table 3.
Incidence of IgA nephropathy among the included international studies
| Study Location | Overall Incidence (Per 100,000) | Time of Data Collection | Reference Population Size | Ages Included, yr | Mean Age, yr | Male (%) |
|---|---|---|---|---|---|---|
| Western Europe | ||||||
| Paris, France | 2.8 | 1994–2001 | 2 million | >18 | 37 | Not reported |
| France | 2.7 | 1976–1990 | 400,000 | 10–80 | 35–55 (over time) | 73% |
| United Kingdom—Scotland | 0.99 | 2000–2014 | 1.5 million | 16–65 | 56.4 | Not reported |
| Northern Ireland | 0.99 | 1976–2005 | 1.7 million | 16–92 | 49 | 80% |
| The Netherlands | 1.9 | 1979–1985 | 1.5 million | 16–65 | Not reported | Not reported |
| Limburg, the Netherlands | 1.9 | 1985–2003 | 630k | Not reported | 41 | 74% |
| Northern Germany | 1.72 | 2002–2008 | 600k | 17–89 | Not reported | 69% |
| Eastern Europe | ||||||
| Czech Republic | 1.12 | 1994–2000 | 10 million | 5–75 | 30 | 68% |
| Czech Republic | 1.16 | 1994–2011 | 10.3 million | 5–75 | 33 | 69% |
| Estonia | 1.4 | 2001–2010 | 1.3 million | Not reported | 39.9 | 64% |
| Asia | ||||||
| Japan | 4.2 | 2009–2010 | 128 million | 9–65 | 39 | 50% |
| Singapore | 1.8 | 1976–2008 | 4.8 million | Not reported | Not reported | Not reported |
| Australia | ||||||
| Australia | 10.5 | 1995–1997 | 4.5 million | 4–75 | Not reported | 66% |
| South America | ||||||
| Peru | 1.7 | 1985–1995 | 6.7 million | Not reported | Not reported | Not reported |
| Brazil | 0.33 | 1993–2007 | 186 million | 19–60 | 35 | 49% |
| Africa | ||||||
| South Africa | 0.06 | 2000–2009 | 3.5 million | 40–60 | 36.8 | Not reported |